Cancers acquire resistance to systemic treatment as a result of clonal evolution and
selection 1 , 2 . Repeat biopsies to study genomic evolution as a result of therapy are difficult, …

Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a 'liquid biopsy…

Plasma of cancer patients contains cell-free tumor DNA that carries information on tumor
mutations and tumor burden. Individual mutations have been probed using allele-specific …

There have been major advances in our understanding of the cellular and molecular biology
of the human malignancies that are collectively referred to as ovarian cancer. At a recent …

Profiling breast cancer with expression arrays has become common, and it has been suggested
that the results from early studies will lead to understanding of the molecular differences …

Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian
carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2 (BRCA) …

High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths,
and overall survival has not changed significantly for several decades. In this Opinion article…

Numerous studies have tested the association between TP53 mutations in ovarian cancer
and prognosis but these have been consistently confounded by limitations in study design, …

Background Granulosa-cell tumors (GCTs) are the most common type of malignant ovarian
sex cord–stromal tumor (SCST). The pathogenesis of these tumors is unknown. Moreover, …

Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on
genomic alterations but have rarely considered the biological properties of plasma cell-free …